BioSpace

Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck

VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.

By BioSpace

1 min read
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights